Eloxx Pharmaceutical is a cutting-edge biopharmaceutical company based in Waltham, MA, specializing in the development of small molecule genetic therapies. With a scientific focus on correcting nonsense mutations and ribosomal mutations, their platform technologies have the potential to revolutionize the treatment of rare genetic diseases and cancer.
Driven by their commitment to innovation, Eloxx is currently focused on developing CELX-02, a novel therapy for Alport Syndrome, a rare kidney disease. Their pipeline also includes promising treatments for other conditions such as RDEB, JEB, and FAP, all targeting the underlying genetic defects responsible for these diseases. With a strong emphasis on scientific research and development, Eloxx Pharmaceuticals is poised to make a significant impact in the field of genetic medicine.
Generated from the website